Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19

Infections, Coronavirus Clinical Trial

Official title:
Open Observational Study of Efficacy and Safety of Polyoxidonium in Complex Therapy of Hospitalized Patients With COVID-19

Status Completed

Clinical Trial Summary

The study is designed as an open observational non-comparative study of Polyoxidonium®, lyophilizate for solution for injections and topical application, 12 mg in hospitalized patients with coronavirus disease (COVID-19).

Clinical Trial Description

The study was planned as an observation of Polyoxidonium® administered in addition to Russian Ministry of Healthcare (MoH) guidance for standard COVID-19 treatment. Regimens have no limitations to the use of concomitant therapy. The aim of the study is to observe the safety and efficacy of Polyoxidonium®, lyophilizate for solution for injections, 12 mg in addition to complex treatment of hospitalized patients with COVID-19. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04542226
Study type	Observational
Source	NPO Petrovax
Contact
Status	Completed
Phase
Start date	March 31, 2020
Completion date	October 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04319172` - Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients
Recruiting	`NCT04511429` - COVID-19 in Immunosuppressed Children
Not yet recruiting	`NCT04385186` - Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19	Phase 2
Active, not recruiting	`NCT04381377` - Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19	Phase 2/Phase 3